Angiotech Pharmaceuticals, Inc.

Details Angiotech Pharmaceuticals, Inc. Angiotech Pharmaceuticals, Inc.

www.angiotech.com

British Columbia

Vancouver

Vancouver

Corporation

active

ANGIOTECH PHARMACEUTICALS INC.
Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX:ANP) is a world
leader in the emerging field of drug-coated medical devices and
biomaterials. We are pioneering the science of adding drugs to
medical devices and biomaterials to dramatically improve their
performance and solve some of medicine€™s most vexing problems.
The Company€™s rapid growth is attributable to the discovery that
the antiproliferative drug, paclitaxel, could also block an
important cellular pathway involved in inflammation. Angiotech€™s
premier formulation of paclitaxel is a stent coating to prevent
restenosis in coronary arteries. Coronary stent sales presently
are US$2.3 billion annually, despite the fact that they fail in
approximately 25 to 50 percent of cases within six months. The
advent of the paclitaxel-eluting stent, which works over 600
percent better than the basic bare stent, has borne compelling
economic arguments and analysts now predict that the industry
will grow to US$5 billion or even as high as $14 billion
annually.
Angiotech is ready to take the same strategy from its drug-
eluting stent program to a whole new level – to countless other
medical device and biomaterials that are placed in the human
body every year. These devices and biomaterials can be greatly
enhanced through co-administration of a drug (such as
paclitaxel) designed to improve the performance of the product.
Major medical device companies are now beginning to recognize
this technological shift. But Angiotech has been anticipating
and preparing for this shift for the past ten years and has
methodically built internal capabilities to lead the effort.
The Company€™s history began in 1992 with the efforts of its Co-
Founder and current president and CEO, William Hunter, MD, MSc,
to build the core technologies that serve as Angiotech€™s
foundation. We€™ve since grown to become one of the largest
pharmaceuticals companies in Canada, but we€™ll continually
strive to redefine and improve therapies in novel and innovative
ways to benefit patients worldwide.
Country of Ownership: Canada
Year Established: 1992
Exporting: Yes
Primary Industry (NAICS): 541690 - Other Scientific and Technical Consulting Services
Primary Business Activity: Services
Total Sales ($CDN): $1,000,000 to $4,999,999
Export Sales ($CDN): $1,000,000 to $4,999,999
Number of Employees: 132

Services:
Drug-loaded biomaterials, Biotechnology

Products:
Paclitaxel stent coatings, Paclitaxel pastes, Paclitaxel films, Paclitaxel gels and creams, Paxceed, Coseal, Costasis, Adhibit

Sector:
Classification Codes
Dun and Bradstreet Number: 253852131

Affiliated with

Also associated with

No associations

Rating

Angiotech Pharmaceuticals, Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.

If you have personal experience with Angiotech Pharmaceuticals, Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotech Pharmaceuticals, Inc. will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-COD-O-17811